Chronic Hepatitis C Treatment with New Antiviral Agents
Recent advances in our knowledge of hepatitis C virus (HCV) molecular biology have enabled improvements in the efficacy and tolerability of HCV treatment, and in this regard many direct-acting antiviral (DAA) agents have been developed. These drugs target specific stages in the HCV life cycle. Phase...
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | Turkish |
| Published: |
Galenos Yayinevi
2018-12-01
|
| Series: | Mediterranean Journal of Infection, Microbes and Antimicrobials |
| Subjects: | |
| Online Access: | http://mjima.org/text.php?&id=114 |
| Summary: | Recent advances in our knowledge of hepatitis C virus (HCV) molecular biology have enabled improvements in the efficacy and tolerability of HCV treatment, and in this regard many direct-acting antiviral (DAA) agents have been developed. These drugs target specific stages in the HCV life cycle. Phase 3 clinical trials have demonstrated treatment success rates of 90% with these drugs and their combinations, while real world data indicate a rate of 80-90%. In this review, the use of DAA drugs in the treatment of chronic HCV infection is reviewed in detail. |
|---|---|
| ISSN: | 2147-673X |